But more importantly, our study showed that MEnZn‐CuO NPs have a role in inducing defective cellular HR repair capacity in ovarian cancer, which allows it to increase the sensitivity of tumors to PARP inhibitors. The gene discussed is PARP1; the disease is ovarian carcinoma.